English Polski
Vol 19 (2024): Continuous Publishing
Case report
Published online: 2024-07-04

open access

Page views 25
Article views/downloads 10
Get Citation

Connect on Social Media

Connect on Social Media

Does cardioverter-defibrillator implantation always means a therapeutic success? – case report

Katarzyna Krajewska12, Michał Peller3, Izabela Kiluk-Witkowska1, Marcin Witkowski1, Anna Lisowska12
DOI: 10.5603/fc.99423


The case report presents a history of a 62-year-old man suffering from heart failure (HF) with reduced ejection fraction of left ventricle (LVEF 35%) in II haemodynamic stage according to NYHA (New York Heart Association), who was admitted to hospital towards ICD (implantable cardioverter-defibrillator) implantation in primary prevention of sudden cardiac death (SCD). During the earlier clinical assessment, the left ventricular (LV) ejection fraction oscillated between 30–33%, but the decision to implant the device was deferred to optimization of heart failure pharmacotherapy. After another 3 months of optimal pharmacotherapy, the LV improvement was poor, therefore it was decided to protect him by ICD implantation. The device was implanted on 17th January 2023. Since that moment, the patient was hospitalized several times because of recurrent ventricular arrhythmia, effectively resolved by ICD therapies. Based on the whole clinical view, the patient was diagnosed with paroxysmal ventricular tachycardia (PVT). Due to the frequent recurrence of arrhythmia and haemodynamic instability during paroxysms, it was decided to perform catheter ablation.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Morawski S, Pruszkowska P, Lenarczyk R, et al. Burza elektryczna – rozpoznanie i leczenie farmakologiczne. Kardiologia po Dyplomie. : 2018.
  2. Hohnloser SH, Al-Khalidi HR, Pratt CM, et al. SHock Inhibition Evaluation with AzimiLiDe (SHIELD) Investigators. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. Eur Heart J. 2006; 27(24): 3027–3032.
  3. Różycka-Kosmalska M, Kaczmarek K, Stec S, et al. Burza elektryczna — ocena kliniczna i postępowanie na oddziale intensywnej terapii kardiologicznej. FC. 2014; 9(3): 254–262.
  4. Exner DV, Pinski SL, Wyse DG, et al. Electrical storm presages non-sudden death: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Circulation. 2001; 103(16): 2066–2071.
  5. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40).
  6. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999; 341(12): 871–878.
  7. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002; 346(12): 884–890.
  8. Trusz-Gluza M. Zaburzenia rytmu serca i przewodzenia. In: Gajewski W. ed. Interna Szczeklika. Medycyna Praktyczna, Kraków 2022: 239–309.
  9. Mazurek M, Lenarczyk R, Kalarus Z, et al. What should medical professionals know about cardioverter-defibrillator? CHSiN. 2014; 11(3): 128–137.